MapLight Therapeutics, Inc.
MPLTNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | |
|---|---|---|
| Revenue | — | — |
| Operating income | −$169.1M | −$82.9M |
| Net income | −$161.2M | −$77.6M |
| Total assets | $479.5M | $136.9M |
| Total liabilities | $21.1M | $21.7M |
| Equity | $458.4M | −$193.6M |
| EPS (diluted) | $-18.56 | $-105.38 |
| Shares out. | 44.0M | 761,276 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −35.2%
- Return on assets
- −33.6%
- Return on capital (ROCE)
- −36.5%
- Liabilities / assets
- 4.4%
- Debt / equity
- 0.05×
- Book value / share
- $10.41
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 22.17safe
- Accruals / assets
- −4.8%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2026-08A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
- Phase 2Enrolling By Invitationreadout ~2027-11ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
- Phase 2Recruitingreadout ~2027-12A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Phase 2Recruitingreadout ~2029-03An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
- Phase 2Recruitingreadout ~2030-02A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- T. Rowe Price Investment Management, Inc.Passive (13G)May 15, 2026
- Forbion Growth Opportunities Fund Iii Cooperatief U.A.Passive (13G)Feb 17, 2026
- Catalyst4, Inc.Activist (13D)Nov 20, 2025
- Novo Holdings A/SActivist (13D)Nov 4, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Kroeger Christopher A.Officer — Chief Executive Officer | May 18, 2026 | Sell | 118,037 | $27.19 |
| Hanson KristopherOfficer — General Counsel | May 11, 2026 | Sell | 284 | $27.61 |
| Kroeger Christopher A.Officer — Chief Executive Officer | May 7, 2026 | Sell | 14,880 | $28.47 |
| Foff Erin PennockOfficer — Chief Medical Officer | May 7, 2026 | Sell | 4,321 | $28.52 |
| Lillie James WoodruffOfficer — Chief Scientific Officer | May 7, 2026 | Sell | 721 | $28.28 |
| Setia VishwasOfficer — Chief Financial Officer | May 4, 2026 | Sell | 4,803 | $27.36 |
| Foff Erin PennockOfficer — Chief Medical Officer | May 4, 2026 | Sell | 9,180 | $27.50 |
| Lillie James WoodruffOfficer — Chief Scientific Officer | May 4, 2026 | Sell | 9,250 | $27.50 |
| Hanson KristopherOfficer — General Counsel | May 4, 2026 | Sell | 9,030 | $27.50 |
| Kroeger Christopher A.Officer — Chief Executive Officer | May 4, 2026 | Sell | 9,136 | $27.50 |
| Gillis JonathanOfficer — CAAO and PAO | Apr 27, 2026 | Sell | 7,914 | $28.94 |
| Kreitzer AnatolOfficer — Chief Discovery Officer | Apr 27, 2026 | Sell | 8,346 | $28.96 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.4M | 5.6 | -22.0% |
| Apr 30, 2026 | 1.7M | 4.9 | +3.7% |
| Apr 15, 2026 | 1.7M | 5.7 | +18.6% |
| Mar 31, 2026 | 1.4M | 4.8 | +4.5% |
| Mar 13, 2026 | 1.4M | 9.5 | +0.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 14, 2026
- Director / officer changeApr 29, 2026
- Results of operations · Regulation FD disclosureMar 26, 2026
- Results of operations · Regulation FD disclosureJan 9, 2026
- Results of operations · Regulation FD disclosureDec 4, 2025
- Unregistered equity sale · Amended charter or bylaws · Other material eventOct 29, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.